Genmab — November 2017
-
Rettelse: det var 66 handelsdag: The Offer Price implies a premium of 46% to the volume-weighted average price of during the sixty SIX trading days prior to the publication of the pre-announcement published on 26 January 2017. Additionally Actelion shareholders will receive one share of the newly created R&D company for each Actelion share they own as a stock dividend
-
Et langstrakt forløb over et år og ganske interessant læsning https://www1.actelion.com/documents/corporate/proposed-transaction/board-report-en.pdf
-
God morgen
-
God morgen.
-
morning... not sure if anyone has acces to Bloodjournal? new article on IMiDs / daratumumab
http://www.bloodjournal.org/content/early/2017/11/22/blood-2017-10-809293
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind